



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	192923	METAGENICS NEUROLIFT
ARTG entry for	Medicine Listed	
Sponsor	Metagenics (Aust) Pty Ltd	
Postal Address	PO Box 675, VIRGINIA BC, QLD, 4014 Australia	
ARTG Start Date	12/12/2011	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . METAGENICS NEUROLIFT

Product Type	Single Medicine Product	Effective Date	3/07/2020
---------------------	-------------------------	-----------------------	-----------

Permitted Indications

Maintain/support general health and wellbeing
Maintain/support healthy thyroid gland function
Aid/assist thyroid hormone production
Enhance/promote body adaptation to stress
Support healthy stress response in the body
Decrease/reduce/relieve symptoms of stress
 Linked indication - Relieve weariness/tiredness/fatigue/feeling of weakness
 Linked indication - Maintain/support mental concentration/focus/clarity
 Linked indication - Decrease/reduce mental/cognitive fatigue
Traditionally used in Ayurvedic medicine to decrease/reduce/relieve symptoms of stress
 Linked indication - Relieve weariness/tiredness/fatigue/feeling of weakness
 Linked indication - Decrease/reduce mental/cognitive fatigue
Support healthy emotional/mood balance

Indication Requirements

Label statement: If symptoms persist, talk to your health professional.
Product presentation must not imply or refer to mental illnesses, disorders or conditions.
Product presentation must not imply or refer to any thyroid related diseases.
Product presentation must not imply or refer to chronic fatigue syndrome.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings



Australian Government
Department of Health and Aged Care
 Therapeutic Goods Administration

This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.

St John's Wort affects the way many prescription medicines work, including the oral contraceptive pill. Consult your doctor.

Individuals who are using prescription anti-depressants or suffer from bipolar depression should not use this product unless under the supervision of a healthcare practitioner (or words to that effect).

If symptoms persist consult your healthcare practitioner (or words to that effect).

Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet.

Additional Product information

Pack Size/Poison information

Pack Size **Poison Schedule**

Components

1 . Formulation 1

Dosage Form Tablet, film coated
Route of Administration Oral

Visual Identification

Active Ingredients

ademetonine disulfate tosylate	98.04 mg
Equivalent: (S)-S-adenosylmethionine	50 mg
calcium folinate	270.3 microgram
Equivalent: folinic acid	250 microgram
colecalfiferol	.005 mg
Hypericum perforatum herb Extract dry concentrate standardised	450 mg
Equivalent: Hypericum perforatum (Dry)	1.935 g
Plectranthus barbatus root Extract dry concentrate	16.67 mg
Equivalent: Plectranthus barbatus (Dry)	500 mg
potassium iodide	98 microgram
Equivalent: iodine	75 microgram
Rhodiola rosea root Extract dry concentrate	36 mg
Equivalent: Rhodiola rosea (Dry)	630 mg
selenomethionine	125 microgram
Equivalent: selenium	50 microgram
Withania somnifera root Extract dry concentrate	150 mg
Equivalent: Withania somnifera (Dry)	1.5 g

Other Ingredients (Excipients)

- Acacia
- calcium hydrogen phosphate dihydrate
- calcium phosphate
- calcium stearate
- croscarmellose sodium
- dl-alpha-tocopherol
- fractionated coconut oil
- hypromellose
- macrogol 8000
- maize starch
- microcrystalline cellulose
- potable water
- silicon dioxide
- stearic acid
- sucrose

Public Summary



Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary